Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
US Lifescience, Wood PLC, Philadelphia, Pennsylvania, USA.
Biotechnol Bioeng. 2021 Sep;118(9):3323-3333. doi: 10.1002/bit.27697. Epub 2021 May 11.
An 8 ton per year manufacturing facility is described based on the framework for integrated and continuous bioprocessing (ICB) common to all known biopharmaceutical implementations. While the output of this plant rivals some of the largest fed-batch plants in the world, the equipment inside the plant is relatively small: the plant consists of four 2000 L single-use bioreactors and has a maximum flow rate of 13 L/min. The equipment and facility for the ICB framework is described in sufficient detail to allow biopharmaceutical companies, vendors, contract manufacturers to build or buy their own systems. The design will allow the creation of a global ICB ecosystem that will transform biopharmaceutical manufacturing. The design is fully backward compatible with legacy fed-batch processes. A clinical production scale is described that can produce smaller batch sizes with the same equipment as that used at the commercial scale. The design described allows the production of as little as 10 g to nearly 35 kg of drug substance per day.
本文描述了一个每年 8 吨的生产设施,该设施基于所有已知生物制药实施中通用的集成和连续生物加工 (ICB) 框架。虽然该工厂的产量可与世界上一些最大的分批补料工厂相媲美,但工厂内部的设备相对较小:该工厂由四个 2000L 的一次性生物反应器组成,最大流量为 13L/min。本文对 ICB 框架的设备和设施进行了详细描述,以便生物制药公司、供应商和合同制造商能够构建或购买自己的系统。该设计将创建一个全球性的 ICB 生态系统,从而彻底改变生物制药制造。该设计与传统的分批补料工艺完全向后兼容。本文还描述了一个临床生产规模,可以使用与商业规模相同的设备生产更小批量的产品。该设计允许每天生产低至 10 克到近 35 公斤的原料药。